In this opening segment, Dr. Thomas Powles sets the stage for a discussion on advanced renal cell carcinoma, emphasizing the critical role of first-line treatment decisions in shaping patient outcomes.

In this segment, Dr. Brian Rini discusses the heterogeneity of tumor biology in advanced renal cell carcinoma and its implications for clinical decision-making.

Why first-line cancer therapy matters: experts weigh proven immunotherapy doublets vs experimental trials, and how tumor biology guides choices.

Learn how experts tailor kidney cancer first-line therapy—IO-TKI for rapid control, dual immunotherapy for low-burden or sarcomatoid disease.

ASCO highlights HIF inhibitors in kidney cancer, showing durable control and strong tolerability as trials test monotherapy vs combination strategies.

Why triplet immunotherapy plus VEGF TKI disappoints in kidney cancer—and how symptoms and tumor burden steer first-line TKI–IO choices.

Learn how clinicians tailor VEGF‑TKI immunotherapy dosing to control cancer fast, curb toxicity, and protect long‑term quality of life.

Experts debate “depth of response” in kidney cancer, warning percentage shrinkage is subjective and variable, while deeper responses generally signal better outcomes.

Clinicians balance cancer control and tolerability by accepting minimal scan “drift,” using qualitative review, and advocating AI volumetric imaging over outdated RECIST.

Clinicians weigh tolerability against slight tumor growth, using patient-shared scan review and calling for AI volumetric imaging to avoid premature therapy switches.

Oncologists weigh FDA approvals, trial data, and real‑world experience to adopt new renal cancer therapies—nimbly, patient by patient.

Kidney cancer treatment shifts toward combo regimens, but missing biomarkers raise overtreatment concerns—experts weigh smarter patient selection.

Experts share patient-centered strategies for first-line clear cell renal cancer, balancing biology, toxicity, breaks, and emerging trial data.